Kidney \<3\> ([Figure 1](#F1){ref-type="fig"}) injury \<4\> molecule-1/T-cell immunoglobulin and mucin domain-containing protein-1 \<5\> (KIM-1/TIM-1 in humans, Kim-1/Tim-1 in rodents) is a type 1 membrane receptor1,2 that is the most highly upregulated protein in the proximal tubule of the injured kidney ([Figure 1](#F1){ref-type="fig"}) \[[@R1]\]. It has also, to varying degrees, been reported to be expressed on immune cells. \[[@R2], [@R3]\]. In the kidney Kim-1 is upregulated in a wide variety of human diseases and in various animal models \[[@R1]\]. A large amount of KIM-1 protein is also shed into the urine, making it a useful urinary biomarker for kidney injury \[[@R1]\]. Kim-1 functions as a phosphatidylserine (PS) receptor which recognizes and internalizes apoptotic cells \[[@R4]\]. Kim-1 also functions as a scavenger receptor, mediating the uptake of modified low density lipoprotein and necrotic cell debris \[[@R4]\]. Kim-1 expression transforms proximal tubular epithelial cells into semiprofessional phagocytes. In the immune system, Kim-1/Tim-1 has been implicated in activation of Th2, Th1 and Th17 differentiation \[[@R2]\]. It has also been proposed to be an activating receptor in B cells, dendritic cells and natural killer T cells \[[@R2], [@R3], [@R5], [@R6]\]. Many of the experiments leading to these conclusions have relied on antibodies against Kim-1/Tim-1, which have been presumed to be agonists or antagonists, or Kim-1/Tim1-Fc fusion proteins as key reagents \[[@R2]\].

In this issue of Kidney International, Nozaki and colleagues report that a low avidity anti-Tim-1 antibody RMT1-10[\*](#FN1){ref-type="fn"} , used as an antagonist of Kim-1/Tim-1, suppressed T cell immune responses and glomerular/tubulointerstitial changes in a model of disease induced by anti-glomerular basement membrane globulin \[[@R7]\]. Treatment with RMT1-10 reduced crescentic glomerulonephritis and Th1/Th17 cellular responses in both systemic immune cells and within the kidney while increasing renal foxp3+ cell and interleukin-10 mRNA, characteristics of regulatory T cells and Th2 cells, respectively. Two other studies have recently demonstrated a partial protection of kidneys by the same RMT1-10 antibody in acute kidney injury (AKI) induced by cisplatin or ischemia reperfusion \[[@R8], [@R9]\]. The authors of these studies also concluded that Kim-1/Tim-1 mediated activation of detrimental T cell and/or innate immune responses \[[@R8], [@R9]\]. Activation of injurious T helper 1 (Th1) cells was inhibited or Th1-related cytokines were diminished by RMT1-10. In the study by Nozaki and colleagues, however, a significant portion of the injected RMT1-10 antibody was shown to accumulate at proximal tubules where Kim-1 is expressed \[[@R7]\]. Given the very high expression of Kim-1/Tim-1 in the kidney relative to its expression in immune cells, care must be taken to interpret the results achieved with the antibody ([Figure 1](#F1){ref-type="fig"}).

Questions have also been raised concerning the RMT1-10 antibody. RMT1-10 was shown to stimulate (not antagonize) Tim-1 on regulatory B cells, a newly identified population whose function in kidney injury is not clear \[[@R6]\]. In addition, RMT1-10 has been reported to be an antagonist of Th1/17 activation and also induced Th2 cytokine expression \[[@R2]\], indicating that the mechanism by which RMT1-10 affects T cell activation is not well defined. Conversely, 3B3 antibody stimulates Th1 activation, even though it binds to the same domain of Tim-1 as RMT1-10 \[[@R2]\]. Recently, using Tim-1 knockout and transgenic mice it was reported that RMT1-4 is the only commercially available Tim-1 specific monoclonal antibody (RMT1-10 was not mentioned) \[[@R5]\]. These studies suggest that the current model for the role of Tim-1 in T cell activation may require revision and the antibody approach requires better definition of mechanism of action.

Several recent findings have suggested that the widely held notion that Tim-1 is a Th2 regulator, requires reconsideration \[[@R2]\]. In studies using Kim-1/Tim-1 knockout mice, Tim-1 expression was very low (or nonexistent) in activated T cells or Th2 cells \[[@R2], [@R5]\]. Additionally, the Tim-1 knockout study demonstrated that Tim-1 may weakly contribute to inflammatory lung injury but not to Th2 cell activation \[[@R2], [@R5]\]. Transgenic expression of Tim-1 in T cells did not stimulate Th2 differentiation \[[@R2], [@R5]\]. Rather, Tim-1 expression was proposed to be present in subsets of activated B cells, dendritic cells and invariant NKT cells \[[@R2], [@R3], [@R5]\], each of which have been implicated in the pathophysiology of kidney injury \[[@R10]\]. The potential function of Tim-1 in renal dendritic cells has not been well characterized \[[@R3]\]. To test the specificity of Tim-1 function in T cells, Rag-1-/- mice were used to evaluate T cell function in cisplatin and ischemia induced kidney injury \[[@R8], [@R9]\]. However, these mice lack both T and B cells. Splenocytes (which contain both T cells and B cells) were used for the adaptive transfer in the ischemia study \[[@R9]\]. Therefore, cells other than T cells might be contributing to the observed effects in Rag-1-/- mice.

Following kidney injury, numerous proximal tubules become KIM-1 positive and copious amounts (nanogram levels) of soluble KIM-1 protein are shed into extracellular spaces, including the urine \[[@R1], [@R4], [@R7]\]. In contrast, few T cells are present in the injured kidney \[[@R7]-[@R9]\] and a very small portion of the activated T cells have been proposed to be Kim-1/Tim-1 positive \[[@R7]\]. For instance, in the report by Nozaki and colleagues Kim-1/Tim-1 positive T cells account for only 2% of all activated CD4+ cells, and very few interstitial CD4+ T cells (1.3 cells/hpf) are found in the GN kidney model \[[@R7]\]. Additionally, immunostaining of Kim-1 in rodent AKI showed an absence of interstitial Kim-1, suggesting Kim-1/Tim-1 expression is predominantly restricted to the tubules \[[@R4]\]. Consequently, there is a dramatic imbalance between nominal Tim-1 expression on a minority of T cells and abundant kidney tubular Kim-1 expression. The abundant amount of tubule and soluble Kim-1/Tim-1 may potentially sequestrate administrated anti-Kim-1/Tim-1 blocking antibodies, as evident in binding of the injected RMT1-10 antibody to the apical side of tubules in the GN model \[[@R7]\]. Thus, inhibitory antibodies may not be the most efficient means of manipulating Kim-1/Tim-1 function on immune cells and T cells may not express very much Kim-1/Tim-1.

Thus, there remain many caveats in interpreting data using antibodies against Kim-1/Tim-1. Antibody blocking experiments will require a standardized antibody with well characterized functional properties and high specificity to Kim-1/Tim-1. In addition Kim-1/Tim-1 cell type specific knockout or transgenic mice, such as CD3 derived T cell or B cell specific transgenic mice and Kim-1/Tim-1 knockout mice \[[@R5]\] can be used to assess the role of Kim-1/Tim-1 in immune cells during kidney injury. Cells isolated from Tim-1 knockout or transgenic mice can also increase the specificity of adaptive transfer experiments. It is likely that Kim-1/Tim-1's phagocytosis/endocytosis function is crucial in tubular injury and repair. Therefore phagocytosis specific functional knockout (mutant) mice and/or Kim-1 specific conditional knockout/transgenic mice should be utilized to evaluate Kim-1's function in the proximal tubule and the immune system. Even though obstacles remain, studies such as those of Nozaki et al using reagents that interfere with or activate Kim-1/Tim-1 should give us important insights into disease mechanisms and potentially lead to specific Kim-1/Tim-1 targeted therapies in humans.

This antibody may not be identical to the commercially available antibody with the same name (Kane L: T cell Ig and mucin domain proteins and immunity. *J Immunol* 184:2743-2749, 2010).
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![Kim-1/Tim-1 is expressed in injured proximal tubule epithelium and shed but may also be expressed in activated lymphocytes and/or myeloid cells in injured kidney. Tubular Kim-1/Tim-1 promotes clearance of apoptotic and necrotic cells but may also contribute to uptake of oxidized lipids if its expression is prolonged. A large amount of Kim-1/Tim-1 is shed to extracellular spaces. It has been proposed that Kim-1/Tim-1 may also be expressed, albeit at much lower levels, by activated lymphocytes and/or myeloid cells in injury-induced immune response. Antibodies can activate cells or prevent ligand binding to Kim-1/Tim-1. They also may interact with shed Kim-1/Tim-1.](nihms-353761-f0001){#F1}
